Research

  • Name:Hailiang Ge

  • Office Location:Room 817-1, No.5 Bldg., West Campus, 280 South Chongqing Rd.,Shanghai

  • Telephone:86-021-64452974

  • Email:gehl@shsmu.edu.cn


Education


1974 Shanghai Jiao Tong University School of Medicine B.S.



1982 Shanghai Jiao Tong University School of Medicine M.M.



1988 Shanghai Jiao Tong University School of Medicine M.D.



Career

1977-1978 Department of surgery, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine     Resident
1978-1985 Department of Biochemistry, Shanghai Jiao Tong University School of Medicine     Assistant Instructor
1985-1987 Department of Nuclear Medicine, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine     Resident
1987-1991 Department of Nuclear Medicine, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine     Visiting Physician
1991-1996 Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine     Assistant Professor
1997-1998 Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine     Associate Professor
1998-1998 Crosby Neurosurgery Research Department of Surgery, School of Medicine University of Michigan     Visiting Scholar
1998-1999 hanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine     Associate Professor
1999-2001 Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine     Professor
2001-2002 Department of Neurology, School of Medicine, University of Pittsburgh      Visiting Scholar
2002-Present Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine     Professor

Research Interests

The research in my laboratory focuses on the biological functions and signal pathway of tumor associated antigen OVA66 and OVA12 in tumorigenesis, which are firstly defined by serological analysis of human ovary cancer of recombinant cDNA expression library (SERXE), have been demonstrated to be highly expressed in the majority of malignant tumors. Our studies have revealed OVA66 might be a novel target for the early detection, prevention and treatment of tumor in the future.

    

                 

Copyright 2016. Shanghai Institute of Immunology,Shanghai Jiao Tong University School of Medicine.All Rights Reserved.